Evaluación de motilidad gástrica mediante electrogastrografía de superficie en pacientes críticos sépticos. Comparación de los efectos de metoclopramida y domperidona: un ensayo clínicopiloto aleatorizado

Asencio, C. Mancilla; Gálvez-Arévalo, L.R.; Tobar, Eduardo; Landskron-Ramos, G.; Madrid-Silva, A.M.

doi:10.1016/j.rgmx.2018.03.007

Cited by 5 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The noninvasive measurement method may be particularly well suited for use in critically ill patients. However, there has been only one study on the use of an electrogastrogram in critically ill patients to date, and further research is warranted [30].…”

Section: Discussionmentioning

confidence: 99%

Visualized Quantitative Evaluation of Gastrointestinal Activity in Healthy Volunteers Using a Noninvasive Single-Channel Electroamplifier

Aikawa,

Kotani,

Sakuramoto

et al. 2023

GastroHep

View full text Add to dashboard Cite

Background. Electrogastrography and electroenterography are noninvasive methods for measuring gastric and intestinal electrical activities, respectively. Few studies have measured electroenterography in healthy humans; however, no studies have measured electrogastrography and electroenterography simultaneously. This study was performed to provide basic electrogastrography and electroenterography data for comparison with future studies in patients. Methods. Simultaneous preprandial and postprandial measurements of electrogastrography and electroenterography were taken for 30 min each in 50 healthy volunteers. Power spectrum analysis was performed to calculate dominant frequency, dominant power, and power ratio. Results. Gastric and small intestinal dominant frequencies were not significantly different between preprandial and postprandial periods. In preprandial and postprandial periods, normogastria was seen in 49 (98%) and 44 (88%) patients ( p = 0.063 ), bradygastria in 1 (2%) and 6 (12%) patients ( p = 0.063 ), and tachygastria in 0 (0%) patients, respectively. Dominant power was significantly increased in the stomach (828 [460–3203] μV2 vs. 1526 [759–2958] μV2, p = 0.016 ) and small intestine (49 [27–86] μV2 vs. 68 [37–130] μV2, p < 0.001 ). The power ratio was 1.6 (0.9–2.5) in the stomach and 1.4 (1.0–2.5) in the small intestine. Body mass index showed a negative correlation with the stomach and small intestinal dominant power in preprandial and postprandial periods ( r s = − 0.566 , p < 0.001 ; r s = − 0.534 , p < 0.001 ; r s = − 0.459 , p < 0.001 ; and r s = − 0.529 , p < 0.001 , respectively). The Bristol Stool Form Scale correlated positively with the small intestinal power ratio ( r s = − 0.430 , p = 0.002 ). Conclusion. There was no change in frequency in the stomach or small intestine, but power significantly increased in both the stomach and small intestine.

show abstract

Section: Discussionmentioning

confidence: 99%

Visualized Quantitative Evaluation of Gastrointestinal Activity in Healthy Volunteers Using a Noninvasive Single-Channel Electroamplifier

Aikawa,

Kotani,

Sakuramoto

et al. 2023

GastroHep

View full text Add to dashboard Cite

show abstract

Simulating human gastrointestinal motility in dynamic in vitro models

Kong

2022

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

The application of dynamic in vitro gastrointestinal (GI) models has grown in popularity to understand the impact of food structure and composition on human health. Given that GI motility is integral to digestion and absorption, a predictive in vitro model should faithfully replicate the motility patterns and motor functions in vivo. In this review, typical characteristics of gastric and small intestinal motility in humans as well as the biomechanical and hydrodynamic events pertinent to gut motility are summarized. The simulation of GI motility in the presently existing dynamic in vitro models is discussed from an engineering perspective and categorized into hydraulic, piston/probe‐driven, roller‐driven, pneumatic, and other systems. Each system and its representative models are evaluated in terms of their motility patterns, the key hydrodynamic characteristics concerning gut motility, their performance in simulating the key physiological events, and their ability to establish in vitro–in vivo correlations. Practical Application: The review paper provided useful information in the design of dynamic GI models and the simulation of human gastric and small intestinal motility which are important for understanding food and health.

show abstract

Treatment of functional dyspepsia in Chinese adult patients with domperidone: A multicenter, randomized, double‐blind, placebo‐controlled pilot study

Fang,

Lin,

et al. 2023

J of Digest Diseases

View full text Add to dashboard Cite

AimsThis pilot study aimed to evaluate domperidone in the treatment of Chinese patients with functional dyspepsia (FD) diagnosed according to Rome IV criteria, including identification of FD subtypes that potentially respond better to domperidone.MethodsThis study was conducted at hospitals in China from Aug 2018 to Jul 2020. The study consisted of a 1‐week screening phase and a 2‐week double‐blind treatment phase. Participants were randomized to domperidone 10 mg or matching placebo tablets three times daily for 14 days. The primary endpoint was overall treatment effect (OTE) response rate after 2 weeks of therapy.ResultsThe study enrolled 160 patients, 80 in each group. The OTE response rate after 2 weeks therapy was numerically higher for domperidone (60.7%) compared with placebo (46.0%) (relative risk [RR], 1.318; 95% confidence interval [CI], 0.972‐1.787). The OTE response rates after 2 weeks by FD subtype for domperidone and placebo were 60.3% vs 54.9% for postprandial distress syndrome (PDS) (RR, 1.098; 95% CI, 0.750‐1.607) and 60.6% vs 35.2% for overlapping PDS‐epigastric pain syndrome (EPS) (RR, 1.722; 95% CI, 0.995‐2.980). Adverse events were reported by seven patients in the domperidone group and twelve patients in the placebo group. None of the adverse events in the domperidone group were serious or unexpected.ConclusionsDomperidone showed a positive pattern on OTE response rates after 2 weeks therapy compared to placebo in patients with FD as well as in subtypes of PDS and overlapping PDS‐EPS. No new safety signal was observed.This article is protected by copyright. All rights reserved.

show abstract

Evaluación de motilidad gástrica mediante electrogastrografía de superficie en pacientes críticos sépticos. Comparación de los efectos de metoclopramida y domperidona: un ensayo clínicopiloto aleatorizado

Abstract: Both metoclopramide and domperidone similarly increased the DF of gastric pacemaker activity and improved gastric motility by restoring a normogastric pattern. Gastric dysmotility is frequent in septic patients.

Cited by 5 publications

References 32 publications

Visualized Quantitative Evaluation of Gastrointestinal Activity in Healthy Volunteers Using a Noninvasive Single-Channel Electroamplifier

Visualized Quantitative Evaluation of Gastrointestinal Activity in Healthy Volunteers Using a Noninvasive Single-Channel Electroamplifier

Simulating human gastrointestinal motility in dynamic in vitro models

Treatment of functional dyspepsia in Chinese adult patients with domperidone: A multicenter, randomized, double‐blind, placebo‐controlled pilot study

Contact Info

Product

Resources

About